Michael Tolentino

Company: Aviceda Therapeutics

Job title: Chief Innovation Officer

Seminars:

Audience Discussion: Optimizing Clinical Trial Design & Navigating Regulatory Landscape for Wet AMD & Diabetic Eye Disease Therapies 8:45 am

Part 1: Diabetic Eye Disease Part 2: Wet AMD Moderated by: Michael Tolentino, Chief Innovation Officer, Aviceda TherapeuticsRead more

day: Day One

An Overview on Pathways & Outcomes of Wet AMD & Diabetic Retinopathy 9:30 am

Exploring molecular pathways contributing to diabetic retinopathy and wet AMD to understand variations in treatment efficacy Identifying key biomarkers that guide the selection of effective therapies and support combination approaches Addressing unmet needs by informing drug development with insights on patients who are unresponsive to current treatmentsRead more

day: Day Two

Fireside Chat: Comparative Market Analysis of Wet AMD Treatments: Trends & Opportunities 3:45 pm

Evaluate the current landscape of anti-VEGF therapies across Wet AMD, highlighting differences in treatment efficacy, patient demographics, and injection frequencies Analyze the economic impact and market penetration of newer treatments like faricimab and biosimilars, considering their uptake and performance in real-world settings compared to traditional therapies Identify emerging trends and unmet needs in each treatment…Read more

day: Day Two

Optimizing Clinical Trial Design for Wet AMD & Diabetic Eye Disease Therapies 9:01 am

This workshop will delve into advanced strategies for designing clinical trials in Wet AMD and diabetic eye disease. By focusing on patient-specific factors, drug delivery challenges, and adaptive trial models, participants will gain the tools needed to enhance trial efficiency and therapeutic success. Structuring trial arms to capture diverse patient populations and ensure comprehensive efficacy…Read more

day: Pre-Conference Day